Paper
0
Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia
Authors
Courtney DiNardo,Brian Jonas
Vinod Pullarkat,Michael Thirman,Jacqueline Garcia,Andrew Wei,Marina Konopleva,Hartmut Döhner,Anthony Letai,Pierre Fenaux,Elizabeth Koller,Violaine Havelange,Brian Leber,Jordi Esteve,Jianxiang Wang,Vlatko Pejša,Roman Hájek,Kimmo Porkka,Árpád Illés,David Lavie,Roberto Lemoli,Kazuhito Yamamoto,Sung‐Soo Yoon,Jun‐Ho Jang,Su‐Peng Yeh,Mehmet Turgut,Wan‐Jen Hong,Ying Zhou,Jalaja Potluri,Keith Pratz
+28 authors
,Zhe YingPublished
Aug 12, 2020
Show more
Save
Tip0
TipSave
Abstract
Older patients with acute myeloid leukemia (AML) have a dismal prognosis, even after treatment with a hypomethylating agent. Azacitidine added to venetoclax had promising efficacy in a previous phase 1b study.
Paper PDF
This paper's license is marked as closed access or non-commercial and cannot be viewed on ResearchHub. Visit the paper's external site.